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Objective: To evaluate the accuracy of the ankle brachial index (ABI) measured with the 
SCVL® (“screening cardiovascular lab”; GenNov, Paris, France), an automated device with 
synchronized arm and ankle cuffs with an automatic ABI calculation.
Methods: Patients were consecutively included in a cardiovascular prevention unit if they 
presented with at least two cardiovascular risk factors. ABI measurements were made using 
the SCVL, following a synchronized assessment of brachial and ankle systolic pressure. These 
values were compared to the ABI obtained with the usual Doppler-assisted method.
Results: We included 157 patients. Mean age was 59.1 years, 56.8% had hypertension, 22.3% 
had diabetes mellitus, and 17.6% were current smokers. An abnormal ABI was observed in 
17.2% with the SCVL and in 16.2% with the Doppler. The prevalence rates of an abnormal 
ABI by patient measured with each device, ie, 15.7% (confidence interval [CI] 0.95: [11.8; 
20.4]) or 14.3% (CI 0.95: [10.7; 18.9]), did not differ. The coefficient of variation of Doppler 
and SCVL measures was 15.8% and 15.1%, respectively. The regression line between the two 
measurement methods was statistically significant. The value-to-value comparison also shows 
a difference of mean equal to 0.010 (CI 0.95: [−0.272; 0.291]) (r = −0.055). Reproducibility 
of ABI   measurements with the SCVL showed a difference of mean equal to 0.009 (CI 0.95: 
[−0.203; 0.222]), without heteroscedasticity (r = −0.003). 
Conclusion: The SCVL is a fast and easy to use automated oscillometric device for the deter-
mination of ABI. The use of this two-synchronized-cuff device correlates well with the gold 
standard Doppler ultrasound method and is reproducible. The SCVL may ease the screening 
for peripheral arterial disease in routine medical practice.
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Introduction
The ankle brachial index (ABI) is an indicator of generalized atherosclerosis. 
In   population cohort studies,1 a low ABI has been related to an increased incidence 
of total and cardiovascular (CV) mortality. The ABI related to increased CV risk 
has been shown to be independent of baseline CV disease and risk factors, sug-
gesting that the ABI might have an independent role in predicting CV events.2 
Also, in a recent meta-analysis it was shown that ABI may improve the accuracy 
of CV risk prediction beyond the Framingham risk score.3 ABI is the ratio of the 
systolic ankle blood pressure (BP) divided by the brachial BP. It is useful for the 
early detection of peripheral arterial disease (PAD) at the physician’s office and 
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also for the assessment of the disease severity.4 Although 
reliable, inexpensive and rather simple, Doppler-assisted 
ABI measurement has several limitations, especially in 
PAD patients in whom distal pulses are missing or difficult 
to detect by Doppler.5
Then, it requires a degree of expertise that has so far 
precluded its widespread adoption in primary care. Moreover, 
the 10% intra observer variability6 and the amount of time 
required to perform Doppler-assisted ABI measurements 
are found to be a drawback for widespread office-based 
  application.7 Lastly, ABI may be falsely normal or even high 
due to arterial calcifications in elderly patients and those with 
diabetes or advanced renal disease.8,9
A test that is automated, easy to perform, and less reliant 
on specialized skills may facilitate measurement of ABI, 
and thus the detection of PAD in susceptible populations.10 
Automated oscillometric determination of BP is approved 
for BP measurement and is commonly available, reliable, 
and simple to use.
The objective of this study was to evaluate the accuracy 
of the ABI as measured with the screening cardiovascular 
lab (SCVL®, GenNov, Paris, France), an automated device 
with synchronized arm and ankle cuffs, in a population of 
patients presenting at least two CV risk factors.
Methods
Population
A total of 157 consecutive patients with or without prior his-
tory of CV disease were included from March to July 2009 
at the Cardiovascular Prevention Unit of the Department of 
Endocrinology and Metabolism at La Pitié-Salpêtrière   Hospital 
in Paris, France. Patients who presented with a recent history 
of arterial claudication were included if they had not already 
undergone surgery. The inclusion criteria consisted of having at 
least two CV risk factors among the following as defined by the 
European guidelines on cardiovascular   prevention11: hyperten-
sion, dyslipidemia, diabetes mellitus, current smoking, familial 
history of premature CV disease, and age .65 years old for 
females or .55 years old for males.   Arterial   hypertension 
was considered present when measurement of brachial BP 
exceeded 140 mmHg (systolic) and/or 90 mm Hg (diastolic) 
on at least two different occasions, or if the patient was on 
antihypertensive medication. Dyslipidemia was defined as 
a total serum cholesterol level of .5.0 mmol/L, serum low-
density lipoprotein (LDL) cholesterol level of .3.0 mmol/L 
serum high-density lipoprotein (HDL) cholesterol level of 
,1.0 mmol/L for men or ,1.2 mmol/L for women, or serum 
triglycerides level of .1.7 mmol/L, or as a daily intake of any 
lipid-lowering medication. Diabetes mellitus was defined by 
fasting blood sugar levels $7.0 mmol/L or HbA1C .6.5%. 
Additionally, the presence of diabetes mellitus was assumed 
if the patient was taking any anti-diabetic treatment. Current 
smoking habits were divided into either current smoking 
(defined as any cigarette in the last month), never smoked or 
smoking stopped. Obesity was defined by a body mass index 
(BMI) .30 kg/m². Moreover, abdominal obesity was defined 
by a waist circumference .102 cm in men and .88 cm in 
women.
Patients underwent complete medical interrogation and 
physical examination. After 12 hours, fasting blood was 
sampled to ascertain levels of glucose, total cholesterol, 
triglycerides, LDL and HDL cholesterol, HbA1C (for   diabetic 
patients) and creatinine. During physical examination, bilat-
eral brachial BP measurements were performed and patients 
were excluded if the inter-arm BP difference was .10 mmHg 
for the systolic or the diastolic BP.
ABI measurements
All measurements were made by the same trained opera-
tor in a temperature-controlled room where each subject 
rested supine for 5 minutes and refrained from smoking, 
heavy exercise, and drinking alcohol or caffeinated bever-
ages for at least 2 hours before measurements were started. 
ABI   measurements were performed as described later 
with both   Doppler assisted and oscillometric techniques 
in all 157 patients. To avoid a possible effect of the order 
of measurements, explorations with the SCVL and the 
Doppler were performed in a random way (using random 
number tables). ABI was measured on both sides as this 
has been demonstrated to be more sensitive for detection 
of PAD.12
Doppler assisted ABI measurement procedure
Doppler-assisted ABI measurements were performed on both 
sides using an automatic OMRON® HEM-907 sphygmoma-
nometer (Omron Healthcare, Kyoto, Japan) with an upper arm 
cuff width ranging between 29 cm and 40 cm and a handheld 
Doppler device with an 8.2 MHz continuous wave. Brachial BP 
was recorded on the right arm using the OMRON device.
Systolic BP was measured for each leg in the dorsalis 
pedis and posterior tibial arteries using the Doppler device 
after placing the cuff just above the ankle. ABI was calculated 
using a computer by dividing the lower value by the higher 
brachial systolic BP.
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Automated ABI measurement procedure
The SCVL is an automated device driven by the USB ports 
of any computer and allows the simultaneous determination 
of BP in the arm and in the ankle with the oscillometric 
method using two synchronized cuffs (Figure 1). The cuff for 
the arm measurement and the pre-shaped cuff for the ankle 
measurement had bladders with sizes of 24 × 12 cm and 
27 × 12 cm, respectively. When the oscillations of pressure 
in a sphygmomanometer cuff are recorded during gradual 
deflation, the point of maximal oscillation corresponds to 
the mean intra-arterial pressure. The oscillation technique 
allows reliable BP measurements by recording oscillations 
of the BP during the cuff deflation. The point of maximal 
oscillation corresponds to the mean intra-arterial pressure 
and the oscillations begin at approximately systolic BP and 
continue below diastolic one, so systolic and diastolic BP 
are estimated indirectly according to the SCVL algorithm. 
The pressure sensor of the device used to measure systolic 
BP at the level of the ankle is different from the pressure 
sensor of the upper arm device to take into account the higher 
pressure needed to compress the artery against the bone at 
the level of the ankle. The SCVL is validated for brachial 
BP measurement according to the protocol of the European 
Society of Hypertension.13 The oscillometric BP readings 
were obtained using the SCVL device, first at the right bra-
chial and ankle arteries and then rotated on the other side 
at the left brachial and ankle arteries. At the ankle level, the 
oscillometric measure reflects all arterial flow at that level, 
also including peroneal arteries. ABI was automatically 
calculated by dividing the ankle value by the higher brachial 
systolic BP recorded. We computed the SCVL and Doppler 
obtained ABIs. To ensure reproducibility, two consecutive 
measurements were performed for each side of each patient. 
Procedure duration was measured on a sample of 30 patients 
and lasted about 3 minutes and 57 seconds.
Statistics
Subject characteristics were expressed as means ± SD or 
  frequencies. For comparison between the two methods, we used 
the ABI as measured by Doppler and the lower of the two SCVL 
measures using a paired Student’s t test and a two-way analy-
sis of variance (ANOVA). The series of values of calculated 
indexes were correlated using linear regression. Agreement 
between the two methods and reproducibility of the SCVL 
measurement were tested by the Bland-Altman analysis.
An ABI  was  considered  as  abnormal  when  it 
was strictly ,0.90 or strictly .1.30. In other words, the 
values between 0.851 and 0.899 or between 1.301 and 1.349, 
often rounded to 0.9 or 1.3 and then considered as normal, 
here were abnormal.
The data were analyzed with XLSTAT 2010.3 software 
(Addinsoft, Paris, France). The 95% two-sided confidence inter-
val (CI 0.95) for a prevalence rate was calculated according to 
the efficient-score method (corrected for continuity) described 
by Newcombe,14 based on the procedure outlined by Wilson.15
Results
Population characteristics
A total of 157 patients were included in the study.   Clinical and 
biological characteristics are shown in Table 1. The mean age 
Figure 1 SCVL® system.
Abbreviation: SCVL, screening cardiovascular lab.
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Table 1 Characteristics of the participants
Characteristic All 
(N = 157)
Male 
(N = 80)
Female 
(N = 77)
Age (years), mean ± SD 59.1 ± 13.2 59.0 ± 12.1 59.2 ± 14.4
Family history of premature CVD, n (%) 47 (36.2) 26 (38.8) 21 (33.3)
Hypertension, n (%) 
Blood pressure (mmHg), mean ± SD 
  Systolic 
  Diastolic 
  Pulse 
Heart rate (beats/minute)
88 (56.8) 
132.1 ± 20.1 
69.2 ± 10.7 
62.9 ± 16.0 
66.5 ± 11.5
41 (51.9) 
131.4 ± 20.5 
68.1 ± 10.9 
63.3 ± 16.2 
65.5 ± 11.4
47 (61.8) 
132.9 ± 19.7 
70.4 ± 10.5 
62.5 ± 15.8 
67.5 ± 11.5
Diabetes mellitus, n (%) 35 (22.3) 17 (21.3) 18 (23.4)
Dyslipidemia, n (%) 
Cholesterol (mmol/L), mean ± SD 
  Total 
  Low density lipoprotein 
  High density lipoprotein 
Triglycerides (mmol/L)
103 (71.0) 
5.48 ± 1.31 
3.49 ± 1.28 
1.37 ± 0.43 
1.37 ± 0.76
54 (73.0) 
5.22 ± 1.33 
3.35 ± 1.25 
1.24 ± 0.38 
1.40 ± 0.78
49 (69.0) 
5.75 ± 1.24 
3.65 ± 1.30 
1.50 ± 0.44 
1.34 ± 0.73
Body-mass index (kg/m²) 
Waist circumference (cm)
26.3 ± 4.8 
93.5 ± 12.5
26.2 ± 3.6 
96.4 ± 10.8
26.5 ± 5.9 
90.5 ± 13.9
Cigarette smoking status, n (%)
  Current 
  Former 
  Never
27 (17.6) 
49 (32.1) 
77 (50.3)
16 (20.2) 
33 (41.8) 
30 (38.0)
11 (14.9) 
16 (21.6) 
47 (63.5)
History of CVD, n (%) 
  Cerebrovascular disease 
  Coronary heart disease 
  Peripheral artery disease
21 (13.4) 
2 (1.3) 
14 (9.3) 
11 (7.0)
15 (18.8) 
1 (1.3) 
11 (14.3) 
6 (7.5)
6 (7.8) 
1 (1.4) 
3 (4.1) 
5 (6.5)
Abbreviations: CVD, cardiovascular disease; SD, standard deviation.
of this population was 59.1 years and 51.0% of patients were 
men. Among the patients 56.8% had treated hypertension, 
22.3% were treated for diabetes mellitus, 71.0% had dys-
lipidemia, 17.6% were current smokers and 50.3% never 
smoked. Further, 41.2% of patients presented with an 
abdominal obesity and 36.2% had a familial history of pre-
mature CV disease. In our population, 21 patients (13.4%) 
had a history of prior CV disease and 11 (7.0%) had an 
already diagnosed PAD.
ABI results
ABI was measured with the two devices in 157 patients 
and therefore 314 legs. The cumulative distribution of 
ABI as obtained by the two methods is shown in Figure 2. 
The means of all Doppler measured ABI on left and right 
sides were not different and equal to 1.02 ± 0.16. The coef-
ficient of variation (CV) was 15.8% for the 314 Doppler 
measures made by one operator. When measured with the 
SCVL device, mean ABI was 1.04 ± 0.15 on the right side 
and 1.03 ± 0.16 on the left side for the first measurement. 
The CV of the SCVL measures was 15.1%. For the second 
measurement with the SCVL device, ABI was 1.05 ± 0.16 
on the right side and 1.04 ± 0.14 on the left side. The paired 
means did not differ. The two-way ANOVA showed neither 
interaction, nor side effect, nor method effect. When 
assessed with the SCVL, 17.2% of the calculated ABI were 
,0.90 and 2.2% were .1.30. When assessed by Doppler, 
16.2% of the calculated ABI were ,0.90 and 1.6% were 
.1.30 as displayed in Figure 2. The prevalence rates of an 
abnormal ABI by patient measured with the SCVL or the 
Doppler, ie, 15.7% (CI 0.95: [11.8; 20.4]) or 14.3% (CI 
0.95: [10.7; 18.9]), did not differ. The regression between 
the two measurements methods was statistically significant: 
r = 0.56, P , 0.0001. The value to value comparison and 
the Bland-Altman analysis assessing the agreement of the 
two methods for all 314 legs also shows a difference of 
mean equal to 0.010 (CI 0.95: [−0.272; 0.291]) with a cor-
relation coefficient between the difference and the average 
equal to −0.055 (CI 0.95: [−0.167; 0.059]) rejecting any 
heteroscedasticity.
Correlations between the two methods of measurement 
are represented in Figure 3. The average time for measure-
ments were not calculated for the 157 patients but were 
roughly estimated by the operator inferior to 5 minutes with 
the SCVL and about more than 10 minutes for the Doppler 
assisted method.
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SCVL reproducibility
Correlations between the two measurements of ABI using 
the SCVL are represented in Figure 4. A positive correla-
tion between the two measurements was observed: r = 0.71, 
P , 0.0001. The value to value comparison and the Bland-
Altman analysis assessing the agreement of the two measure-
ments for all the 314 legs also shows a difference of mean 
equal to 0.009 (CI 0.95: [−0.203; 0.222]). The plot and the 
correlation coefficient between the difference and the aver-
age equal to −0.003 (CI 0.95: [−0.117; 0.110]) revealed no 
systematic trend for heteroscedasticity.
Discussion
In our population of 157 patients, we found a good concor-
dance between ABI as measured by the reference method 
and ABI as measured by the SCVL. We also found the ABI 
measurement with the SCVL to be reproducible.
The prevention of CV diseases is based on identification 
of high risk patients and the presence of a low ABI has been 
demonstrated to have an independent value in predicting the 
risk of CV events.2 The reference method for ABI calculation 
is the Doppler ultrasound method and requires dedicated 
equipment, training, and is at least a 10–15 minute test 
with an operator-dependent result. These constraints limit 
the broad use of ABI in medical practice. A simple, faster, 
and accurate method should facilitate the ABI evaluation in 
patients with CV risk factors and will help in the detection 
of subjects with an augmented risk of CV events.
The SCVL is an automated device using two   synchronized 
cuffs to determine ABI. It showed good measurement repro-
ducibility in our study. When compared to the reference 
method for assessing ABI, the regression analysis showed a 
strong correlation between the two methods and the Bland-
Altman analysis indicated only a small difference between 
values. Furthermore, this new automated method has a 
strong correlation with the standard manual Doppler method 
in classified subjects with an abnormal ABI. One major 
advantage of this new method is its ease of use, as it does 
not need special equipment (such as a Doppler probe) and 
requires only very minimal user training. It is also a much 
faster measurement than the standard Doppler method. The 
use of a single device with two automatically synchronized 
cuffs rather than sequential BP measurements using the 
user-dependent Doppler methods is also a major advantage. 
ABI by SCVL
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Figure 2 Cumulative distribution of ABI as obtained by SCVL® and Doppler.
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Figure 4 SCVL® reproducibility.
Abbreviation: SCVL, screening cardiovascular lab.
Because of these reasons, the SCVL will help to extend the 
number of ABI assessments in routine clinical practice.
In our population, the prevalence of PAD as defined by 
the determination of an ABI , 0.90 or .1.30 was 15.7% 
according to measurements made by the SCVL device and 
14.3% according to the Doppler method. Prevalence of PAD 
varies across populations based on the groups and the detec-
tion methods used. Studies have shown that measuring the 
ABI in patients above the age of 70 or above the age of 50 in 
patients with diabetes or smokers should yield a positive rate 
of approximately 29%.16 In unselected patients above the 
age of 65, disease prevalence approaches 20%17 and would 
be closer to 10% between 40 and 60 years of age in studies 
using Doppler measurements of ABI18 or in lipid clinics.19 
Diabetes and tobacco are the main causes of PAD among the 
different major CV risk factors and our population counted 
only 50% of current or former smokers, 22% of diabetics 
whereas 57% of our patients presented with hypertension 
and 71% with dyslipidemia. This can explain the relatively 
low prevalence of PAD in our population compared to the 
PARTNERS Study.16
Our results confirm previous studies that have found that 
oscillometric measurements are a useful tool for assessment of 
ABI. A study involving patients recruited in office practice stud-
ies showed a sensitivity of 73% or 88% and a specificity of 85% 
or 95% for detection of PAD using oscillometric   methods.10 
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Another study where subjects were recruited in a cardiology 
department demonstrated a sensitivity of 73% and specificity 
of 95% when compared to the reference Doppler assisted ABI 
measurement.20 Accordingly, the oscillometric measurement 
of ABI is appropriate in such population.
Limitations of this study are as follows. It is an observa-
tional study on a selected population of patients who do not 
reflect the general population but is still characteristic of 
the target population in which PAD should be detected.21
In conclusion, our study demonstrated that the auto-
mated determination of ABI using the SCVL, an automated 
device with two synchronized cuffs, correlates well with 
the reference Doppler ultrasound method. Because of the 
quick and easy procedure for ABI determination using the 
SCVL device, it is possible to imagine that, after validation 
by larger randomized trials and cost effective analysis, a 
greater number of ABI measurements could be performed in 
asymptomatic subjects with CV risk factors, a population in 
which ABI evaluation is recommended but is not currently 
realized in medical practice.
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